Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 16.

Strasser, F; Blum, D; von Moos, R; Cathomas, R; Ribi, K; Aebi, S; Betticher, D; Hayoz, S; Klingbiel, D; Brauchli, P; Haefner, M; Mauri, S; Kaasa, S; Koeberle, D (2016). The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06). Annals of Oncology, 27(2):324-332.

Body, J; Henry, D; von Moos, R; Rider, A; De Courcy, J; Murray, G; Bhowmik, D; Gatta, F; Arellano, J; Hechmati, G; Qian, Y (2015). Bone pain and bone targeting agent (Bta) treatment pattern in patients with bone metastases (Bms) from prostate cancer (Pc) in real world setting in Europe. Value in Health, 18(7):A493.

Koeberle, D; Betticher, D C; von Moos, R; Dietrich, D; Brauchli, P; Baertschi, D; Matter, K; Winterhalder, R; Borner, M; Anchisi, S; Moosmann, P; Kollar, A; Saletti, P; Roth, A; Frueh, M; Kueng, M; Popescu, R A; Schacher, S; Hess, V; Herrmann, R (2015). Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Annals of Oncology, 26(4):709-714.

Joerger, M; Baty, F; Früh, M; Droege, C; Stahel, R A; Betticher, D C; von Moos, R; Ochsenbein, A; Pless, M; Gautschi, O; Rothschild, S; Brauchli, P; Klingbiel, D; Zappa, F; Brutsche, M (2014). Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer, 85(2):306-313.

Zappa, F; Droege, C; Betticher, D; von Moos, R; Bubendorf, L; Ochsenbein, A; Gautschi, O; Oppliger Leibundgut, E; Froesch, P; Stahel, R; Hess, T; Rauch, D; Schmid, P; Mayer, M; Crowe, S; Brauchli, P; Ribi, K; Pless, M (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). Lung Cancer, 78(3):239-244.

von Moos, R; Seifert, B; Simcock, M; Goldinger, S M; Gillessen, S; Ochsenbein, A; Michielin, O; Cathomas, R; Schläppi, M; Moch, H; Schraml, P H; Mihic-Probst, D; Mamot, C; Schönewolf, N; Dummer, R (2012). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of Oncology, 23(2):531-536.

Schraml, P; von Teichman, A; Mihic-Probst, D; Simcock, M; Ochsenbein, A; Dummer, R; Michieilin, O; Seifert, B; Schläppi, M; Moch, H; von Moos, R (2012). Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncology Reports, 28(2):654-658.

Achtari, C; Fink, D; Günthert, A R; Huober, J; Pestalozzi, B; Petignat, P; von Moos, R; Sessa, C (2011). Bevacizumab in the primary treatment of epithelial ovarian cancer – some comments on the latest results. Schweizer Krebs-Bulletin = Bulletin Suisse du Cancer, 35(1):35-38.

Dummer, R; Guggenheim, M; Arnold, A W; Braun, R; von Moos, R (2011). Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Swiss Medical Weekly, 141:w13320.

Hasler-Strub, U; von Moos, R (2010). Breast cancer: screening, treatment and follow-up. Praxis, 99(7):413-418.

Rochlitz, C; Senn, H-J; Betticher, D; Helbling, D; von Moos, R; Pestalozzi, B; Thürlimann, B; Uebelhart, D; Aapro, M (2010). Der Einsatz von Bisphosphonaten bei der Behandlung solider Tumoren. Swiss Medical Forum, 10(34):562-564.

Hitz, F; Martinelli, G; Zucca, E; von Moos, R; Mingrone, W; Simcock, M; Peterson, J; Cogliatti, S B; Bertoni, F; Zimmermann, D R; Ghielmini, M (2009). A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. Hematological Oncology, 27(3):154-159.

Ruhstaller, T; von Moos, R; Rufibach, K; Ribi, K; Glaus, A; Spaeti, B; Koeberle, D; Mueller, U; Hoefliger, M; Hess, D; Boehme, C; Thuerlimann, B (2009). Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study. Oncology, 76(2):142-148.

von Moos, R; Thuerlimann, B J K; Aapro, M; Rayson, D; Harrold, K; Sehouli, J; Scotte, F; Lorusso, D; Dummer, R; Lacouture, M E; Lademann, J; Hauschild, A (2008). Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. European Journal of Cancer, 44(6):781-790.

von Moos, R; Strasser, F; Gillessen, S; Zaugg, K (2008). Metastatic bone pain: treatment options with an emphasis on bisphosphonates. Supportive Care in Cancer, 16(10):1105-1115.

Strasser, F; Lutz, T A; Maeder, M T; Thuerlimann, B; Bueche, D; Tschöp, M; Kaufmann, K; Holst, B; Brändle, M; von Moos, R; Demmer, R; Cerny, T (2008). Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer, 98:300-308.

This list was generated on Thu Nov 23 16:29:51 2017 CET.